Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Tobacco/Nicotine Use Disorder (TUD)

Ketamine for Tobacco/Nicotine Use Disorder (TUD)

7 papers and 2 clinical trials exploring ketamine as a treatment for tobacco/nicotine use disorder (tud).

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication1.3 billion smokers worldwide.

Tobacco/Nicotine Use Disorder (TUD)

Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.

Full Tobacco/Nicotine Use Disorder (TUD) profile

Academic Research

7 papers
Open Accessindividual

Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study

This randomised crossover study (n=18) tested a single sub-anesthetic ketamine infusion against midazolam in adults with tobacco use disorder who were not trying to quit smoking. Ketamine was well tolerated but did not clearly reduce smoking, craving or withdrawal, although some participants reported stronger psychological effects and found abstaining easier afterwards.

Published
April 30, 2026
Journal
Brain Sciences
Authors
Luzum, N. R., McCall, M. H., Talley Boyd, C., Columbano, H., Ip, E., Saldana, S., Oliveto, A. H., Addicott, M.
Paywallindividual

Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial

This multicenter, randomised, placebo-controlled clinical trial (n=236) investigates the efficacy and safety of esketamine (ESK) (8x35mg) for smoking cessation in patients with lung cancer and major depressive disorder (MDD). Eight weekly intranasal ESK sessions significantly improved both self-reported (44.1%) and biologically verified (28.8%) smoking abstinence at 6-month follow-up, alongside reductions in depression, anxiety, nicotine dependence, and respiratory symptoms.

Published
August 1, 2025
Journal
Journal of Affective Disorders
Authors
Hong, C. J.
Open Accessmeta

The Acute Effects of Psychoactive Drugs on Emotional Episodic Memory Encoding, Consolidation, and Retrieval

This review shows that acute psychoactive drugs differentially affect emotional episodic memory depending on timing: drugs given before encoding can selectively impair (GABAA sedatives, THC, ketamine), enhance (dopaminergic/noradrenergic stimulants), or produce mixed effects (MDMA) on emotional versus neutral memories. GABAA sedatives administered immediately post‑encoding preferentially enhance consolidation of emotional memories (with specificity declining as retrieval is delayed), and intoxication at retrieval (THC, dextroamphetamine, MDMA) increases false memories—especially for positive content—while the authors outline neural mechanisms, methodological considerations and implications for recreational and medical use.

Published
June 2, 2022
Journal
Psyarxiv
Authors
Doss, M. K., de Wit, H., Gallo, D. A.
Paywallindividual

Family of Structurally Related Bioconjugates Yields Antibodies with Differential Selectivity against Ketamine and 6-Hydroxynorketamine

This mouse study investigated the development of immunopharmacotherapies to generate antibodies against ketamine and its metabolites. It finds that specific hapten designs successfully elicited antibody responses with high affinity for ketamine or 6-hydroxynorketamine, offering a potential pathway for treating overdose or restricting metabolite access to the brain.

Published
October 15, 2021
Journal
ACS Chemical Neuroscience
Authors
Zheng, Z., Kyzer, J. L., Worob, A., Wenthur, C. J.
Paywallmeta

Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature

This paper (2021) reviews the current literature regarding LSD, psilocybin, ketamine, ibogaine, and ayahuasca as potential treatments for addiction. The authors conclude that the available evidence is promising, but that more robust research is needed.

Published
March 31, 2021
Journal
SN Comprehensive Clinical Medicine
Authors
Nigam, K. B., Pandurangi, A. K.
Open Accessmeta

Can psychedelic compounds play a part in drug dependence therapy?

The paper reviews renewed interest in psychedelic-assisted therapies for drug dependence, summarising emerging studies of psilocybin, ketamine, ibogaine and ayahuasca. Despite clinical and legal limitations, it argues that the potential to improve patient outcomes warrants further research.

Published
January 2, 2018
Journal
British Journal of Psychiatry
Authors
Sessa, B., Johnson, M. W.

Clinical Trials

2 trials
CompletedPhase I

Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder

Single-group pilot interventional study (n=7) evaluating IM ketamine administered weekly for three weeks combined with brief motivational enhancement therapy for tobacco use disorder.

Started
May 2, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05796791
CompletedPhase I

The Effects of Sedatives on Tobacco Use Disorder Version 2 (SED-TUD2)

This double-blind, randomised, placebo-controlled, crossover mechanistic trial (n=52) tested single IV infusions of ketamine (0.71 mg/kg), midazolam (0.025 mg/kg), dexmedetomidine (0.025 mg/kg), or saline in non-treatment-seeking smokers.

Started
January 31, 2023
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT05505630

Explore further

Search all Ketamine papers Search all Tobacco/Nicotine Use Disorder (TUD) trials Full Ketamine profile Full Tobacco/Nicotine Use Disorder (TUD) profile